CRSP

CRISPR Therapeutics AG remains a long-term Buy, anchored by Casgevy's commercial success and management's execution in ex vivo gene editing. Casgevy's Q2 sales grew 78% sequentially, reinforcing its blockbuster potential despite market skepticism and slow initial uptake. Anthropic's AI-driven gene editing discovery introduces potential competitive and funding risks, but clinical impact appears distant.

CRISPR Therapeutics owns the only approved gene therapy of its kind, yet the stock sits far below where Wall Street thinks it belongs.

Even if it's not being officially reported yet, its drug Casgevy is accruing revenue that will show up in earnest beginning next year. That being said, CRISPR Therapeutics' developmental pipeline shows promise well beyond Casgevy's potential.

CRISPR Therapeutics will likely be a much larger company in 10 years. Much of that time will be spent refining the technologies it already has in hand today.

Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?

CRISPR Therapeutics (CRSP) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

CRISPR Therapeutics NASDAQ: CRSP CEO Sam Kulkarni outlined the company's commercial and clinical priorities during a Morgan Stanley discussion, highlighting continued adoption of CASGEVY and expected data updates across several pipeline programs by the end of 2026.

CRISPR Therapeutics AG (CRSP) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Genomics is reshaping healthcare, with WGS, NEO and NTLA advancing diagnostics and precision medicine.

ZUG, Switzerland and BOSTON, Sept. 08, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP) today announced that members of its senior management team will present at the Morgan Stanley 24th Annual Global Healthcare Conference on Monday, September 14, 2026 at 1:05 p.m.